Company intelligence / Profile preview

BioSelf Technology

Ownership: Private
Employees: ~17
Development stage: Commercial

Overview

BioSelf Technology developed the Sensate device, a patented consumer neurotech product that uses infrasonic resonance to stimulate the vagus nerve and improve heart rate variability, providing rapid stress relief. The technology has been recognized by TIME Magazine as a Best Invention of 2022 and achieved significant commercial traction with a $10.2M revenue run rate at end of 2022. There are no traditional clinical trial results reported.

Therapeutic areas: Psychiatry
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

HBL/Hosiden Besson (manufacturing collaboration for launch of Sensate device in UK/EU markets)

Beyond the preview

Go deeper on BioSelf Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSelf Technology.

Explore the full profile